Literature DB >> 29551180

When a policy decision meets practice realities: The case of cancer survivorship care and rehabilitation needs assessment.

Charlotte Handberg1, Sally Thorne2, Thomas Maribo3.   

Abstract

PURPOSE: To analyze and describe health professionals' attitudes and perspectives on the complexities of cancer survivorship and rehabilitation needs assessment in a shared cancer care context.
METHOD: The design and methodology for this study was Interpretive Description and the analysis was informed by Symbolic Interactionism as the theoretical framework. Between April and December 2015 an ethnographic fieldwork was carried out by the first author in haematological wards at two Danish hospitals and in two primary care settings conducting cancer survivorship care programs. Participants were 41 health professionals working with needs assessment.
RESULTS: The findings revealed an understanding of the health professionals' attitudes and perspectives and were distinguishable in relation to three structural conditions associated with the dimensions of survivorship care: Patient Context, Workplace Priorities and Practice Culture. Despite shared beliefs that needs assessment was essential to ensure survivorship care, the differential conditions surrounding the hospital and the primary care settting impeded the wider idea of formalized needs assessment, creating barriers to a seamless link between the sectors.
CONCLUSIONS: Meaningful resolution of these disjunctures will require broad solutions, recognizing that the organization of healthcare into disconnected systems, with their different conditions, history, habits and traditions, will certainly plague the "transition" problems in healthcare unless a wider perspective is taken. Thoughtful and informed clinicians working with decision makers and those who know the evidence and can interpret systems in context can certainly bring better options to light in order to develop high quality survivorship care that will support patients throughout their cancer trajectory.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Cancer survivorship care; Collaboration; Health professionals; Hospitals; Needs assessment; Policy makers; Primary care; Rehabilitation; Survivorship care

Mesh:

Year:  2018        PMID: 29551180     DOI: 10.1016/j.ejon.2018.01.010

Source DB:  PubMed          Journal:  Eur J Oncol Nurs        ISSN: 1462-3889            Impact factor:   2.398


  5 in total

1.  Supportive care interventions and quality of life in advanced disease prostate cancer survivors: An integrative review of the literature.

Authors:  Alejandra Calvo-Schimmel; Suparna Qanungo; Susan D Newman; Katherine R Sterba
Journal:  Can Oncol Nurs J       Date:  2021-11-01

2.  A Cross-Sectional Study Evaluating Potential Differences in the Need for Cancer Survivorship Care in Relation to Patients' Socioeconomic Status.

Authors:  Charlotte Handberg; Marie Louise Svendsen; Thomas Maribo
Journal:  J Clin Med Res       Date:  2019-06-11

3.  Systematic screening as a tool for individualized rehabilitation following primary breast cancer treatment: study protocol for the ReScreen randomized controlled trial.

Authors:  U Olsson Möller; L Rydén; M Malmström
Journal:  BMC Cancer       Date:  2020-05-29       Impact factor: 4.430

4.  Cross-sectorial collaboration on policy-driven rehabilitation care models for persons with neuromuscular diseases: reflections and behavior of community-based health professionals.

Authors:  Charlotte Handberg; Ulla Werlauff
Journal:  BMC Health Serv Res       Date:  2022-09-17       Impact factor: 2.908

5.  What are the attitudes of health professionals regarding patient reported outcome measures (PROMs) in oncology practice? A mixed-method synthesis of the qualitative evidence.

Authors:  Bróna Nic Giolla Easpaig; Yvonne Tran; Mia Bierbaum; Gaston Arnolda; Geoff P Delaney; Winston Liauw; Robyn L Ward; Ian Olver; David Currow; Afaf Girgis; Ivana Durcinoska; Jeffrey Braithwaite
Journal:  BMC Health Serv Res       Date:  2020-02-10       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.